VCYT - Veracyte Stock Price, News & Analysis

$6.55 0.06 (0.92 %)
(As of 11/22/2017 04:00 PM ET)
Previous Close$6.49
Today's Range$6.46 - $6.66
52-Week Range$5.75 - $9.80
Volume108,734 shs
Average Volume129,772 shs
Market Capitalization$217.85 million
P/E RatioN/A
Dividend YieldN/A
Beta1.9

About Veracyte (NASDAQ:VCYT)

Veracyte logoVeracyte, Inc. is a genomic diagnostics company. The Company uses genomic technology to resolve diagnostic ambiguity. It targets diseases in which patients undergo invasive diagnostic procedures. Its products combine genomic technology, clinical science and machine learning. The Company commercializes over three genomic tests, which are transforming the diagnosis of thyroid cancer, lung cancer and idiopathic pulmonary fibrosis. The Company’s commercial solution, the Afirma Thyroid fine needle aspiration (FNA) Analysis, centers on the Afirma Gene Expression Classifier (GEC). The Afirma GEC is offered directly or as part of a solution that also includes cytopathology. The Company operates in the pulmonology diagnostics market. It offers Percepta Bronchial Genomic Classifier, a genomic test to resolve ambiguity in lung cancer diagnosis. It also offers the Envisia Genomic Classifier, which is designed to help in the assessment of patients suspected to have idiopathic pulmonary fibrosis.


Industry, Sector and Symbol:
  • Industry: Bio Diagnostics & Testing
  • Sub-Industry: N/A
  • Sector: Medical
  • Symbol: NASDAQ:VCYT
  • CUSIP: N/A
  • Web: www.veracyte.com
Debt:
  • Debt-to-Equity Ratio: 0.59%
  • Current Ratio: 5.19%
  • Quick Ratio: 4.86%
Sales & Book Value:
  • Annual Sales: $65.08 million
  • Price / Sales: 3.43
  • Book Value: $1.26 per share
  • Price / Book: 5.20
Profitability:
  • Trailing EPS: ($0.81)
  • Net Income: $-31,350,000.00
  • Net Margins: -38.19%
  • Return on Equity: -52.99%
  • Return on Assets: -29.50%
Misc:
  • Employees: 216
  • Outstanding Shares: 34,040,000
 

Frequently Asked Questions for Veracyte (NASDAQ:VCYT)

What is Veracyte's stock symbol?

Veracyte trades on the NASDAQ under the ticker symbol "VCYT."

How were Veracyte's earnings last quarter?

Veracyte, Inc. (NASDAQ:VCYT) posted its quarterly earnings data on Monday, November, 6th. The biotechnology company reported ($0.21) EPS for the quarter, hitting the Zacks' consensus estimate of ($0.21). The biotechnology company had revenue of $17.50 million for the quarter, compared to analyst estimates of $19.54 million. Veracyte had a negative return on equity of 52.99% and a negative net margin of 38.19%. The company's revenue was down 5.9% on a year-over-year basis. During the same quarter last year, the company earned ($0.20) EPS. View Veracyte's Earnings History.

Where is Veracyte's stock going? Where will Veracyte's stock price be in 2017?

5 analysts have issued 12 month price objectives for Veracyte's stock. Their forecasts range from $9.00 to $15.00. On average, they anticipate Veracyte's stock price to reach $12.50 in the next twelve months. View Analyst Ratings for Veracyte.

What are Wall Street analysts saying about Veracyte stock?

Here are some recent quotes from research analysts about Veracyte stock:

  • 1. According to Zacks Investment Research, "Veracyte, Inc. is a diagnostics company. It is focused on discovering, developing and commercializing molecular cytology solutions. The Company provides Afirma Thyroid FNA Analysis, which helps physicians in reducing unnecessary diagnostic surgeries for patients with thyroid nodules. Veracyte is also developing Afirma Malignant GEC test. It serves endocrinologists, radiologists, and head and neck specialists. Veracyte, Inc. is headquartered in South San Francisco, California. " (11/10/2017)
  • 2. Leerink Swann analysts commented, "We reiterate our OP rating and maintain our PT of $12. Commercial Payers Still Key to Driving Adoption Ramp and Sales Longer-term. VCYT has successfully driven the Afirma adoption ramp by gaining multi-year commercial payer contracts on the back of solid clinical evidence — as 80% of Afirma volumes still comes from private payers. Afirma currently has 185M lives covered and $155M contracted with 25M of those lives in Blue Cross Blue Shield. Beyond that, for Afirma GEC, VCYT’s key priorities include securing a positive coverage decision for the largest Blues payer: Anthem (ANTM, OP) with its 40M covered lives, and converting other Blues payers to in-network contracts. Medicare accounts for only 20% of Afirma test samples and thus the eliminated impact was only ~$1.6M. Plus, with the new data that was released at the ATA meeting recently highlighting 70%-80% of specificity of the enhanced Afirma test, we believe VCYT should be able to get Anthem as well." (11/22/2016)

Who are some of Veracyte's key competitors?

Who are Veracyte's key executives?

Veracyte's management team includes the folowing people:

  • Bonnie H. Anderson, Chairman of the Board, Chief Executive Officer (Age 58)
  • Christopher M. Hall, President, Chief Operating Officer (Age 48)
  • Keith S. Kennedy, Chief Financial Officer (Age 47)
  • Julie A. Brooks, General Counsel, Secretary (Age 71)
  • John W. Hanna, Chief Commercial Officer
  • John L. Bishop, Lead Independent Director (Age 72)
  • Fred E. Cohen Ph.D. M.D., Independent Director (Age 60)
  • Karin Eastham CPA, Independent Director (Age 67)
  • Robert S. Epstein M.D., Independent Director (Age 62)
  • Kevin K. Gordon, Independent Director (Age 54)

Who owns Veracyte stock?

Veracyte's stock is owned by many different of retail and institutional investors. Top institutional investors include Cortina Asset Management LLC (2.03%), Axiom International Investors LLC DE (1.14%), Stonepine Capital Management LLC (0.97%), Essex Investment Management Co. LLC (0.54%), Schwab Charles Investment Management Inc. (0.48%) and Birchview Capital LP (0.35%). Company insiders that own Veracyte stock include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones and Jesse I Treu. View Institutional Ownership Trends for Veracyte.

Who sold Veracyte stock? Who is selling Veracyte stock?

Veracyte's stock was sold by a variety of institutional investors in the last quarter, including Stonepine Capital Management LLC and Cortina Asset Management LLC. Company insiders that have sold Veracyte company stock in the last year include Bonnie H Anderson, Christopher M Hall, Evan/ Fa Jones and Jesse I Treu. View Insider Buying and Selling for Veracyte.

Who bought Veracyte stock? Who is buying Veracyte stock?

Veracyte's stock was purchased by a variety of institutional investors in the last quarter, including Essex Investment Management Co. LLC, Axiom International Investors LLC DE, Schwab Charles Investment Management Inc., Perkins Capital Management Inc., Quantum Capital Management, Algert Global LLC, OxFORD Asset Management LLP and Trexquant Investment LP. View Insider Buying and Selling for Veracyte.

How do I buy Veracyte stock?

Shares of Veracyte can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is Veracyte's stock price today?

One share of Veracyte stock can currently be purchased for approximately $6.55.

How big of a company is Veracyte?

Veracyte has a market capitalization of $217.85 million and generates $65.08 million in revenue each year. The biotechnology company earns $-31,350,000.00 in net income (profit) each year or ($0.81) on an earnings per share basis. Veracyte employs 216 workers across the globe.

How can I contact Veracyte?

Veracyte's mailing address is 6000 SHORELINE COURT SUITE 300, SOUTH SAN FRANCISCO CA, 94080. The biotechnology company can be reached via phone at 650-243-6300 or via email at [email protected]


MarketBeat Community Rating for Veracyte (VCYT)

Community Ranking:  3.3 out of 5 (star star star)
Outperform Votes:  201 (Vote Outperform)
Underperform Votes:  101 (Vote Underperform)
Total Votes:  302
MarketBeat's community ratings are surveys of what our community members think about Veracyte and other stocks. Vote "Outperform" if you believe the stock will outperform the S&P 500 over the long term. Vote "Underperform" if you believe the stock will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

Analysts' Consensus Rating for Veracyte (NASDAQ:VCYT)

  (How are Consensus Ratings Calculated?)
Ratings Breakdown: 0 Sell Ratings, 2 Hold Ratings, 3 Buy Ratings, 0 Strong Buy Ratings
Consensus Rating:Buy (Score: 2.60)
Consensus Price Target: $12.50 (90.84% upside)

Consensus Price Target History for Veracyte (NASDAQ:VCYT)

Price Target History for Veracyte (NASDAQ:VCYT)

Analysts' Ratings History for Veracyte (NASDAQ:VCYT)

Show:
DateFirmActionRatingPrice TargetImpact on Share PriceDetails
11/20/2017BTIG ResearchSet Price TargetBuy$13.00N/AView Rating Details
11/7/2017Leerink SwannLower Price TargetOutperform$12.00 -> $9.00N/AView Rating Details
11/7/2017Janney Montgomery ScottDowngradeBuy -> NeutralN/AView Rating Details
11/7/2017Piper Jaffray CompaniesDowngradeOverweight -> NeutralN/AView Rating Details
5/18/2017Cantor FitzgeraldSet Price TargetBuy$13.00LowView Rating Details
10/18/2016William BlairReiterated RatingOutperformN/AView Rating Details
(Data available from 11/22/2015 forward)

Earnings

Earnings History and Estimates Chart for Veracyte (NASDAQ:VCYT)

Earnings by Quarter for Veracyte (NASDAQ:VCYT)

Earnings History by Quarter for Veracyte (NASDAQ VCYT)

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
11/6/2017Q3 2017($0.21)($0.21)$19.54 million$17.50 millionViewN/AView Earnings Details
7/31/2017Q2 2017($0.25)($0.22)$18.32 million$18.40 millionViewN/AView Earnings Details
5/3/2017Q1 2017($0.24)($0.24)$18.09 million$16.43 millionViewListenView Earnings Details
3/1/2017Q416($0.26)($0.14)$17.49 million$18.30 millionViewListenView Earnings Details
11/3/2016Q316($0.36)($0.20)$15.76 million$18.60 millionViewN/AView Earnings Details
8/3/2016Q216($0.33)($0.40)$14.80 million$14.68 millionViewN/AView Earnings Details
5/5/2016Q116($0.35)($0.36)$13.08 million$13.55 millionViewN/AView Earnings Details
3/10/2016Q415($0.30)($0.29)$14.45 million$14.04 millionViewListenView Earnings Details
11/5/2015Q315($0.33)($0.32)$12.72 million$12.33 millionViewListenView Earnings Details
8/13/2015Q215($0.31)($0.35)$12.23 million$11.90 millionViewListenView Earnings Details
5/14/2015Q115($0.37)($0.34)$10.83 million$11.20 millionViewListenView Earnings Details
3/19/2015Q414($0.33)($0.36)$11.83 million$12.20 millionViewN/AView Earnings Details
11/13/2014Q314($0.35)($0.37)$9.67 million$9.80 millionViewN/AView Earnings Details
8/13/2014Q214($0.33)($0.31)$9.36 million$8.70 millionViewN/AView Earnings Details
5/8/2014Q114($0.31)($0.32)$7.19 million$7.50 millionViewN/AView Earnings Details
3/18/2014Q4($0.38)($0.42)$6.43 million$6.84 millionViewListenView Earnings Details
11/25/2013Q313($6.59)$3.20 million$5.60 millionViewN/AView Earnings Details
(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Veracyte (NASDAQ:VCYT)
2017 EPS Consensus Estimate: ($0.93)
2018 EPS Consensus Estimate: ($0.64)
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20171($0.22)($0.22)($0.22)
Q2 20172($0.27)($0.26)($0.27)
Q3 20171($0.23)($0.23)($0.23)
Q4 20172($0.22)($0.21)($0.22)
Q1 20182($0.19)($0.18)($0.19)
Q2 20182($0.17)($0.15)($0.16)
Q3 20182($0.16)($0.14)($0.15)
Q4 20182($0.15)($0.13)($0.14)
(Data provided by Zacks Investment Research)

Dividends

Dividend History for Veracyte (NASDAQ:VCYT)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading and Institutional Ownership History for Veracyte (NASDAQ VCYT)

Insider Ownership Percentage: 13.40%
Institutional Ownership Percentage: 69.03%
Insider Trades by Quarter for Veracyte (NASDAQ:VCYT)
Insider Trades by Quarter for Veracyte (NASDAQ:VCYT)

Insider Trades by Quarter for Veracyte (NASDAQ VCYT)

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/20/2017Bonnie H AndersonChairmanSell16,000$9.41$150,560.00View SEC Filing  
10/18/2017Bonnie H AndersonCEOSell6,000$9.09$54,540.00View SEC Filing  
10/2/2017Christopher M HallInsiderSell20,000$9.00$180,000.00View SEC Filing  
9/25/2017Bonnie H AndersonChairmanSell6,000$8.44$50,640.00View SEC Filing  
8/28/2017Evan/ Fa JonesDirectorSell22,500$7.81$175,725.00View SEC Filing  
8/24/2017Evan/ Fa JonesDirectorSell40,000$7.88$315,200.00View SEC Filing  
8/23/2017Evan/ Fa JonesDirectorSell20,000$7.92$158,400.00View SEC Filing  
5/16/2017Jesse I TreuDirectorSell2,226$8.08$17,986.08View SEC Filing  
3/21/2017Bonnie H AndersonChairmanSell5,000$9.09$45,450.00View SEC Filing  
6/3/2016Bonnie H AndersonCEOBuy5,000$5.40$27,000.00View SEC Filing  
6/1/2016Bonnie H AndersonCEOBuy5,000$5.46$27,300.00View SEC Filing  
5/31/2016Bonnie H AndersonCEOBuy2,500$5.46$13,650.00View SEC Filing  
11/25/2015Evan/ Fa JonesDirectorSell7,896$7.23$57,088.08View SEC Filing  
11/24/2015Evan/ Fa JonesDirectorSell7,104$7.20$51,148.80View SEC Filing  
7/22/2015Christopher M HallCOOSell2,500$11.85$29,625.00View SEC Filing  
6/26/2015Shelly D GuyerCFOSell1,000$12.08$12,080.00View SEC Filing  
9/10/2014Christopher M HallInsiderSell1,000$12.29$12,290.00View SEC Filing  
9/9/2014Evan/ Fa JonesDirectorSell27,304$12.60$344,030.40View SEC Filing  
8/18/2014Christopher M HallInsiderSell1,000$12.92$12,920.00View SEC Filing  
7/29/2014Julie BrooksEVPBuy1,122$14.69$16,482.18View SEC Filing  
7/28/2014Julie BrooksEVPBuy1,000$14.71$14,710.00View SEC Filing  
7/22/2014Julie BrooksVPBuy2,000$14.18$28,360.00View SEC Filing  
7/21/2014Julie BrooksVPBuy1,000$14.00$14,000.00View SEC Filing  
7/10/2014Christopher M HallInsiderSell3,000$14.92$44,760.00View SEC Filing  
6/27/2014Bonnie H AndersonCEOSell1,000$17.95$17,950.00View SEC Filing  
6/23/2014Bonnie H AndersonCEOSell4,000$16.45$65,800.00View SEC Filing  
6/23/2014Christopher M HallInsiderSell2,000$16.95$33,900.00View SEC Filing  
6/20/2014Shelly D GuyerCFOSell1,250$16.04$20,050.00View SEC Filing  
6/19/2014Christopher M HallInsiderSell3,000$14.99$44,970.00View SEC Filing  
6/12/2014Evan/ Fa JonesDirectorSell16,650$15.07$250,915.50View SEC Filing  
6/9/2014Evan/ Fa JonesDirectorSell22,870$14.57$333,215.90View SEC Filing  
6/5/2014Evan/ Fa JonesDirectorSell28,248$14.33$404,793.84View SEC Filing  
5/30/2014Evan/ Fa JonesDirectorSell23,882$15.33$366,111.06View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Veracyte (NASDAQ VCYT)

Source:
DateHeadline
BTIG Research Analysts Give Veracyte, Inc. (VCYT) a $13.00 Price TargetBTIG Research Analysts Give Veracyte, Inc. (VCYT) a $13.00 Price Target
www.americanbankingnews.com - November 21 at 8:14 PM
Veracyte, Inc. (VCYT) Expected to Post Quarterly Sales of $18.84 MillionVeracyte, Inc. (VCYT) Expected to Post Quarterly Sales of $18.84 Million
www.americanbankingnews.com - November 19 at 10:36 AM
Financial Survey: Invitae Corporation (NVTA) and Veracyte (VCYT)Financial Survey: Invitae Corporation (NVTA) and Veracyte (VCYT)
www.americanbankingnews.com - November 18 at 5:42 PM
Veracyte to Present at the Piper Jaffray 29th Annual Healthcare ConferenceVeracyte to Present at the Piper Jaffray 29th Annual Healthcare Conference
finance.yahoo.com - November 16 at 5:08 AM
Veracyte, Inc. (VCYT) Receives Average Recommendation of "Hold" from BrokeragesVeracyte, Inc. (VCYT) Receives Average Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - November 13 at 10:54 AM
Veracyte Announces New Clinical Utility Data Suggesting Envisia Genomic Classifier Enables as Confident a Diagnosis in IPF as Surgical PathologyVeracyte Announces New Clinical Utility Data Suggesting Envisia Genomic Classifier Enables as Confident a Diagnosis in IPF as Surgical Pathology
finance.yahoo.com - November 12 at 1:06 PM
Veracyte, Inc. (VCYT) Stock Rating Upgraded by Zacks Investment ResearchVeracyte, Inc. (VCYT) Stock Rating Upgraded by Zacks Investment Research
www.americanbankingnews.com - November 10 at 8:37 AM
FY2017 Earnings Forecast for Veracyte, Inc. Issued By Leerink Swann (VCYT)FY2017 Earnings Forecast for Veracyte, Inc. Issued By Leerink Swann (VCYT)
www.americanbankingnews.com - November 9 at 6:22 AM
Veracyte, Inc. (VCYT) Given New $9.00 Price Target at Leerink SwannVeracyte, Inc. (VCYT) Given New $9.00 Price Target at Leerink Swann
www.americanbankingnews.com - November 7 at 2:30 PM
Veracyte Announces Third Quarter 2017 Financial ResultsVeracyte Announces Third Quarter 2017 Financial Results
finance.yahoo.com - November 7 at 12:59 PM
Edited Transcript of VCYT earnings conference call or presentation 6-Nov-17 9:30pm GMTEdited Transcript of VCYT earnings conference call or presentation 6-Nov-17 9:30pm GMT
finance.yahoo.com - November 7 at 12:58 PM
Veracyte, Inc. (VCYT) Posts  Earnings ResultsVeracyte, Inc. (VCYT) Posts Earnings Results
www.americanbankingnews.com - November 7 at 9:06 AM
Veracyte, Inc. (VCYT) Stock Rating Lowered by Janney Montgomery ScottVeracyte, Inc. (VCYT) Stock Rating Lowered by Janney Montgomery Scott
www.americanbankingnews.com - November 7 at 8:33 AM
CORRECTING and REPLACING Veracyte Announces Presentation of New Clinical Utility Data at CHEST 2017 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer DiagnosisCORRECTING and REPLACING Veracyte Announces Presentation of New Clinical Utility Data at CHEST 2017 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis
finance.yahoo.com - November 4 at 6:08 AM
Veracyte to Present at the Canaccord Genuity Medical Technologies & Diagnostics ForumVeracyte to Present at the Canaccord Genuity Medical Technologies & Diagnostics Forum
finance.yahoo.com - November 2 at 10:51 AM
Veracyte Announces Presentation of New Clinical Utility Data at CHEST 2017 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer DiagnosisVeracyte Announces Presentation of New Clinical Utility Data at CHEST 2017 Showing Percepta Classifier Reduces Invasive Procedures in Lung Cancer Diagnosis
finance.yahoo.com - November 1 at 10:23 AM
Veracyte, Inc. (VCYT) Expected to Announce Quarterly Sales of $19.96 MillionVeracyte, Inc. (VCYT) Expected to Announce Quarterly Sales of $19.96 Million
www.americanbankingnews.com - October 30 at 8:23 AM
 Analysts Anticipate Veracyte, Inc. (VCYT) Will Post Earnings of -$0.21 Per Share Analysts Anticipate Veracyte, Inc. (VCYT) Will Post Earnings of -$0.21 Per Share
www.americanbankingnews.com - October 28 at 7:34 AM
Veracyte to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial Results on Monday, November 6, 2017Veracyte to Host Conference Call and Webcast to Discuss Third Quarter 2017 Financial Results on Monday, November 6, 2017
finance.yahoo.com - October 26 at 12:04 PM
Veracyte, Inc. (VCYT) Scheduled to Post Earnings on WednesdayVeracyte, Inc. (VCYT) Scheduled to Post Earnings on Wednesday
www.americanbankingnews.com - October 25 at 3:48 AM
Veracyte Announces New Data Highlighting Performance of the Afirma GSC Ensemble Machine Learning Algorithms in Challenging Thyroid Cancer Subtypes to Be Presented at ATAVeracyte Announces New Data Highlighting Performance of the Afirma GSC Ensemble Machine Learning Algorithms in Challenging Thyroid Cancer Subtypes to Be Presented at ATA
finance.yahoo.com - October 22 at 7:46 AM
Veracyte, Inc. (VCYT) CEO Bonnie H. Anderson Sells 6,000 SharesVeracyte, Inc. (VCYT) CEO Bonnie H. Anderson Sells 6,000 Shares
www.americanbankingnews.com - October 20 at 7:44 PM
Bonnie H. Anderson Sells 16,000 Shares of Veracyte, Inc. (VCYT) StockBonnie H. Anderson Sells 16,000 Shares of Veracyte, Inc. (VCYT) Stock
www.americanbankingnews.com - October 20 at 7:44 PM
Veracyte Announces Presentation of New Data Validating Accuracy of BRAF V600E and Parathyroid Tissue Classifiers at ATA Annual MeetingVeracyte Announces Presentation of New Data Validating Accuracy of BRAF V600E and Parathyroid Tissue Classifiers at ATA Annual Meeting
finance.yahoo.com - October 20 at 4:20 PM
Veracyte (VCYT) Announces New Data Demonstrating Clinical Utility of Percepta Bronchial Genomic Classifier to be Presented at CHESTVeracyte (VCYT) Announces New Data Demonstrating Clinical Utility of Percepta Bronchial Genomic Classifier to be Presented at CHEST
www.streetinsider.com - October 20 at 9:52 AM
Veracyte Announces New Data Demonstrating Clinical Utility of Percepta Bronchial Genomic Classifier to be Presented at CHEST Annual Meeting 2017Veracyte Announces New Data Demonstrating Clinical Utility of Percepta Bronchial Genomic Classifier to be Presented at CHEST Annual Meeting 2017
finance.yahoo.com - October 20 at 9:52 AM
Veracyte, Inc. (VCYT) Receives Consensus Recommendation of "Hold" from BrokeragesVeracyte, Inc. (VCYT) Receives Consensus Recommendation of "Hold" from Brokerages
www.americanbankingnews.com - October 19 at 9:07 AM
Veracyte Chairman and CEO Bonnie Anderson Receives Prestigious Innovation Award at Biomedical Engineering Society Annual MeetingVeracyte Chairman and CEO Bonnie Anderson Receives Prestigious Innovation Award at Biomedical Engineering Society Annual Meeting
finance.yahoo.com - October 14 at 9:09 AM
Veracyte, Inc. (VCYT) Downgraded to Sell at Zacks Investment ResearchVeracyte, Inc. (VCYT) Downgraded to Sell at Zacks Investment Research
www.americanbankingnews.com - October 12 at 10:22 AM
 Analysts Anticipate Veracyte, Inc. (VCYT) Will Post Quarterly Sales of $19.96 Million Analysts Anticipate Veracyte, Inc. (VCYT) Will Post Quarterly Sales of $19.96 Million
www.americanbankingnews.com - October 11 at 11:54 AM
Veracyte Announces Data From Five Studies Validating the Next-Generation Afirma Genomic Sequencing Classifier to Be Presented at ATA 2017 Annual MeetingVeracyte Announces Data From Five Studies Validating the Next-Generation Afirma Genomic Sequencing Classifier to Be Presented at ATA 2017 Annual Meeting
finance.yahoo.com - October 6 at 12:23 PM
Veracyte, Inc. (VCYT) Cut to Hold at Zacks Investment ResearchVeracyte, Inc. (VCYT) Cut to Hold at Zacks Investment Research
www.americanbankingnews.com - October 5 at 11:58 PM
Veracyte, Inc. (VCYT) Insider Christopher M. Hall Sells 20,000 SharesVeracyte, Inc. (VCYT) Insider Christopher M. Hall Sells 20,000 Shares
www.americanbankingnews.com - October 4 at 8:30 PM
Veracyte Announces Release of 2018 Preliminary Reimbursement Rate for Afirma Genomic Classifier Under PAMAVeracyte Announces Release of 2018 Preliminary Reimbursement Rate for Afirma Genomic Classifier Under PAMA
finance.yahoo.com - October 3 at 2:25 PM
Insider Selling: Veracyte, Inc. (VCYT) Chairman Sells 6,000 Shares of StockInsider Selling: Veracyte, Inc. (VCYT) Chairman Sells 6,000 Shares of Stock
www.americanbankingnews.com - September 27 at 8:32 PM
Veracyte, Inc. (VCYT) Given Average Recommendation of "Buy" by BrokeragesVeracyte, Inc. (VCYT) Given Average Recommendation of "Buy" by Brokerages
www.americanbankingnews.com - September 24 at 8:44 AM
 Brokerages Expect Veracyte, Inc. (VCYT) to Announce -$0.21 EPS Brokerages Expect Veracyte, Inc. (VCYT) to Announce -$0.21 EPS
www.americanbankingnews.com - September 20 at 12:30 PM
Veracyte Launches Campaign to Save Lives through Early Screening for Lung CancerVeracyte Launches Campaign to Save Lives through Early Screening for Lung Cancer
finance.yahoo.com - September 19 at 9:14 AM
Awareness Campaign Takes Lung Cancer Risk Head-On, Asking North Carolinians To Screen TogetherAwareness Campaign Takes Lung Cancer Risk Head-On, Asking North Carolinians To Screen Together
finance.yahoo.com - September 19 at 9:14 AM
Veracyte to Present at the Cantor Fitzgerald Global Healthcare ConferenceVeracyte to Present at the Cantor Fitzgerald Global Healthcare Conference
finance.yahoo.com - September 13 at 10:55 AM
Veracytes (VCYT) "Buy" Rating Reaffirmed at Piper Jaffray CompaniesVeracyte's (VCYT) "Buy" Rating Reaffirmed at Piper Jaffray Companies
www.americanbankingnews.com - September 12 at 5:08 PM
Veracyte, Inc. (VCYT) Forecasted to Earn Q4 2018 Earnings of ($0.13) Per ShareVeracyte, Inc. (VCYT) Forecasted to Earn Q4 2018 Earnings of ($0.13) Per Share
www.americanbankingnews.com - September 7 at 2:26 PM
Brokers Offer Predictions for Veracyte, Inc.s Q1 2018 Earnings (VCYT)Brokers Offer Predictions for Veracyte, Inc.'s Q1 2018 Earnings (VCYT)
www.americanbankingnews.com - September 6 at 9:29 AM
Veracyte, Inc. (VCYT) Expected to Post Quarterly Sales of $20.20 MillionVeracyte, Inc. (VCYT) Expected to Post Quarterly Sales of $20.20 Million
www.americanbankingnews.com - September 3 at 1:22 AM
Veracyte, Inc. (VCYT) Receives New Coverage from Analysts at BTIG ResearchVeracyte, Inc. (VCYT) Receives New Coverage from Analysts at BTIG Research
www.americanbankingnews.com - August 31 at 7:46 AM
Veracyte, Inc. (VCYT) Receives Consensus Rating of "Buy" from BrokeragesVeracyte, Inc. (VCYT) Receives Consensus Rating of "Buy" from Brokerages
www.americanbankingnews.com - August 30 at 8:48 AM
Insider Selling: Veracyte, Inc. (VCYT) Director Sells 22,500 Shares of StockInsider Selling: Veracyte, Inc. (VCYT) Director Sells 22,500 Shares of Stock
www.americanbankingnews.com - August 29 at 8:12 PM
Evan/ Fa Jones Sells 20,000 Shares of Veracyte, Inc. (VCYT) StockEvan/ Fa Jones Sells 20,000 Shares of Veracyte, Inc. (VCYT) Stock
www.americanbankingnews.com - August 25 at 8:32 PM
Veracyte, Inc. (VCYT) Director Sells $315,200.00 in StockVeracyte, Inc. (VCYT) Director Sells $315,200.00 in Stock
www.americanbankingnews.com - August 25 at 8:08 PM
Veracyte to Present at the Morgan Stanley 15th Annual Global Healthcare ConferenceVeracyte to Present at the Morgan Stanley 15th Annual Global Healthcare Conference
finance.yahoo.com - August 25 at 12:13 PM

Social Media

Financials

Chart

Veracyte (NASDAQ VCYT) Chart for Wednesday, November, 22, 2017
Loading chart…

This page was last updated on 11/22/2017 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.